Navigation Links
Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor
Date:6/22/2010

Adoption of iCardiac’s Next Generation Cardiac Safety Solutions Continues to Accelerate.

(PRWEB) June 22, 2010 -- iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced today that an additional three top 20 pharmaceutical companies have recently selected iCardiac as a preferred vendor. iCardiac will provide a full range of cardiac safety, ECG and blood pressure monitoring services and advanced analytics, including Highly Automated QT(sm) and Dynamic QT beat-to-beat(sm), as well as end-to-end global study logistics including ECG, Holter, and ABPM equipment deployment.

“We continue to see increased market demand for the next generation of cardiac safety solutions which provide more reliable results and improved resource efficiencies,” said Sasha Latypova, Executive Vice President. “The accelerated pace of adoption of our solutions is a testament to the superior scientific and business value, as well as the quality of service delivered by the dedicated and experienced team of cardiac safety professionals at iCardiac.”

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the “gold standard” manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.

About iCardiac Technologies
iCardiac Technologies, Inc., provides drug development companies worldwide with the complete range of next generation cardiac safety core lab services. Its team of cardiac safety experts collectively bring over 100 years of cardiology, electrophysiology, drug development, regulatory and academic experience. The iCardiac team pioneered the field of Highly Automated QT evaluation as well as controlling for autonomic nervous system effects on the QT interval, a phenomenon estimated to produce false-positive results in conventional QT studies for as many as 25% of all molecules currently in clinical development. iCardiac’s services are supported by the COMPAS technology platform which maximizes the precision and decreases the cost of cardiac safety assessment from First-in-Human studies to Phase III studies. This suite of tools, which complies with the FDA’s ICH E14 QT/QTc guidance for Through QT Studies (TQT), was originally developed and validated at the University of Rochester’s Heart Research Follow Up Program (HRFUP), as well as in Pfizer’s Research and Development programs. iCardiac’s analytics have been used for over a decade in support of clinical trials. For more information, visit www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/2010/06/prweb4164084.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. IGEN Networks Corp. announces new Board member and the cancellation of three million shares for return to treasury
2. Asymchem Laboratories Hires Three New Employees: Guojie Xu, Pingzhong Huang, and Xiaojun Huang
3. Three Nephrology TreatmentTrends Publications from BioTrends Provide a Comprehensive View of Bone and Mineral Metabolism Practice Patterns Around the Globe
4. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
5. Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement
6. Millipore Sponsors Three Academic Memberships for the MetaMiner Stem Cell Project
7. Laureate Pharma Welcomes Three New Members to Business Development Team
8. ViroPharma to Present at Three November Healthcare Conferences
9. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
10. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
11. Virginia Now Owns Three Top National Business Rankings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 2017   Valentin A. Pavlov, PhD , associate ... and CEO of The Feinstein Institute for Medical ... how the nervous system regulates the immune system, which ... medicine devices to treat disease and injury. The ... The paper examines various studies which further ...
(Date:1/16/2017)... Jan. 16, 2017  Eurofins Genomics today announced the ... more customers to receive their primers in a shorter ... in quality found with other providers. Express oligos are ... at no additional fee. Researchers ... studies, including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. ...
(Date:1/14/2017)... -- The Alliance for Safe Biologic Medicines (ASBM) today issued ... guidance on biologic naming: We commend ... importance of distinct naming for all biologics, including biosimilars. ... will bring to patients, including new treatment options and ... the Guidance dealing with suffix design remains at odds ...
(Date:1/13/2017)... Research and Markets has announced the addition of ... ... grow at a CAGR of 16.83% during the period 2017-2021. ... the global biopolymers market for 2017-2021. To calculate the market size, the ... products. The report also includes a a discussion of the key vendors ...
Breaking Biology Technology:
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/16/2016)... 2016 The global wearable medical device market, in terms ... from USD 5.31 billion in 2016, at a CAGR of 18.0% ... ... advancements in medical devices, launch of a growing number of smartphone-based ... among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):